-
1.发明公开公开(公告)号：US20240074973A1
公开(公告)日：2024-03-07
申请号：US18269474
申请日：2021-12-23
发明人： Naoki OGURA , Yu KAJIWARA , Koushi FUJISAWA , Yoshihiko ESAKI , Koji SAKANAKA , Toyomi FUJISAWA , Yuko TONE
CPC分类号： A61K9/107 , A61K9/0014 , A61K31/55 , A61K47/14 , A61P27/14
摘要： The present invention provides a pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient which can maintain the concentration of the active ingredient for a long time even at lower concentrations.
-
公开(公告)号：US20240058356A1
公开(公告)日：2024-02-22
申请号：US18269452
申请日：2021-12-23
发明人： Toyomi FUJISAWA , Hiroyuki IKEDA
IPC分类号： A61K31/55 , A61K9/00 , A61K9/107 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/44
CPC分类号： A61K31/55 , A61K9/0048 , A61K9/107 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/44
摘要： The present invention provides a pharmaceutical composition for transdermal administration comprising epinastine or a salt thereof as an active ingredient which can maintain the effective concentration of epinastine or a salt thereof in an ocular tissue and stabilize epinastine or a salt thereof in the pharmaceutical composition for a long time.
-
公开(公告)号：US11793798B2
公开(公告)日：2023-10-24
申请号：US17521031
申请日：2021-11-08
IPC分类号： A61K31/444 , A61P27/06 , A61P27/02 , A61K9/00
CPC分类号： A61K31/444 , A61K9/0048 , A61P27/02 , A61P27/06
摘要： Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
-
公开(公告)号：US20230190716A1
公开(公告)日：2023-06-22
申请号：US18170246
申请日：2023-02-16
发明人： Hideki Miyake , Tomoko ODA , Daisuke SHII
IPC分类号： A61K31/436 , A61K9/00 , A61K31/675
CPC分类号： A61K31/436 , A61K9/0048 , A61K31/675
摘要： A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
-
公开(公告)号：US20220072012A1
公开(公告)日：2022-03-10
申请号：US17414285
申请日：2019-12-17
发明人： Masatomo KATO , Tomoko ODA , Kazutaka KIDO
IPC分类号： A61K31/575 , A61K9/00 , A61P27/10
摘要： The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20210059997A1
公开(公告)日：2021-03-04
申请号：US16958571
申请日：2018-12-27
发明人： Masaya OKI , Fumito KANADA , Kazuma KAMATA , Yoshihiro TAKAMURA , Seiji MIYAKE , Masaru INATANI , Hiroyuki UCHIDA , Miho NOGATA , Masatomo KATO , Koushi FUJISAWA , Shinji TAKAOKA
IPC分类号： A61K31/4439 , A61K31/192 , A61K9/00 , A61P27/12 , A61K31/4406
摘要： Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.
-
公开(公告)号：US20190255026A1
公开(公告)日：2019-08-22
申请号：US16405249
申请日：2019-05-07
发明人： Hideki MIYAKE , Tomoko ODA , Daisuke SHII
IPC分类号： A61K31/436 , A61K9/00 , A61K31/675
摘要： A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
-
![[4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF](/abs-image/US/2019/04/11/US20190106393A1/abs.jpg.150x150.jpg)
8.发明申请公开(公告)号：US20190106393A1
公开(公告)日：2019-04-11
申请号：US16210163
申请日：2018-12-05
发明人： Kenji KAWASHIMA , Yusuke YAMAZAKI , Shinji TAKAOKA , Daisuke SHII , Tomoko ODA , Takahiro MATSUYAMA
IPC分类号： C07D241/44 , C07F9/6509 , A61P29/00 , A61P27/02 , C07D403/12 , A61K31/675 , A61K31/5377 , A61K31/498
CPC分类号： C07D241/44 , A61K31/498 , A61K31/5377 , A61K31/675 , A61P27/02 , A61P29/00 , C07D403/12 , C07F9/650994
摘要： The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
-
公开(公告)号：US20180246081A1
公开(公告)日：2018-08-30
申请号：US15964210
申请日：2018-04-27
发明人： Hideki MIYAKE , Tomoko ODA
IPC分类号： G01N33/50 , A61K31/7052 , A01K67/027 , A61K45/00
CPC分类号： G01N33/5088 , A01K67/027 , A01K2207/25 , A01K2227/105 , A01K2267/035 , A61K31/7052 , A61K45/00 , G01N33/5082 , G01N2500/10 , G01N2800/162
摘要： A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
-
公开(公告)号：US20180169079A1
公开(公告)日：2018-06-21
申请号：US15895100
申请日：2018-02-13
IPC分类号： A61K31/444 , A61K9/00
CPC分类号： A61K31/444 , A61K9/0048 , A61P27/02 , A61P27/06
摘要： Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
-
-
-
-
-
-
-
-
-
搜索结果
452 条记录 (耗时 0.023 秒)
